CD279 (PD-1) Mouse anti-Human, Brilliant Violet 421, Clone: MIH4, BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 564323
The MIH4 monoclonal antibody specifically binds to the program death 1 (PD-1) receptor CD279, a member of the Ig superfamily. CD279 is an immunoregulatory receptor expressed on activated T cells, B cells and myeloid cells. Mice deficient in CD279 show a breakdown of peripheral tolerance and manifest multiple autoimmune symptoms. It contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region. PD-L1 and PD-L2 are ligands of CD279 and are members of the B7 gene family. Interaction of CD279:PD-Ligands results in inhibition of T cell proliferation and cytokine secretion. Reports suggest that the B7/CTLA-4 pathway functions primarily to attenuate, limit, and/or terminate naοve T-cell activation in secondary lymphoid organs. The PD-ligand:CD279 pathway, on the other hand, may primarily attenuate, limit, and/or terminate T-, B-, and myeloid cell activation/effector function at sites of inflammation in the periphery.
The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.
|PD-1; hPD-1; PD1; PDCD1; Programmed cell death 1; SLEB2|
|Human PD-1 Transfected Cell Line|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
|Brilliant Violet 421|
|Aqueous buffered solution containing BSA and ≤0.09% sodium azide|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok